Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke (LA BICHAT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00163150|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : March 14, 2008
|Condition or disease||Intervention/treatment||Phase|
|Cerebrovascular Accident Hypercholesterolemia||Drug: Atorvastatin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||128 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.|
|Study Start Date :||June 2003|
|Actual Study Completion Date :||February 2006|
- Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3.
- Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00163150
|Pfizer Investigational Site|
|Paris, Cedex 18, France, 75877|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|